绝经期激素治疗中的孕激素:双刃剑
Olavi Ylikorkala1, Johanna M Joensuu1, Heli Siitonen1
1Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Seminars in reproductive medicine
|May 16, 2025
概括
孕激素保护子宫内膜,但增加乳腺癌和深静脉血栓形成的风险. 持续使用提供了最好的保护,一些孕激素在乳腺癌风险方面可能更安全.
科学领域:
- 生殖医学 生殖医学
- 妇科 妇科 妇科 妇科
- 内分泌学 在内分泌学.
背景情况:
- 对更年期症状的雌激素治疗需要对子宫内膜进行保护.
- 孕激素通常被添加到雌激素中,以预防子宫内膜增生和癌症.
- 存在各种孕激素和施用途径,每个都有独特的配置文件.
研究的目的:
- 审查与雌激素一起用于子宫内膜保护的不同孕激素的疗效和安全性.
- 评估孕激素对乳腺癌风险,血栓形成和其他健康结果的影响.
- 评估孕激素在子宫内膜安全方面的最佳使用情况.
主要方法:
- 对与雌激素一起使用的孕激素 (诺列乙酸,麦德罗西孕激素乙酸,狄德罗,微化孕激素,莱文诺格斯特勒,多斯皮伦,三重孕激素) 的系统审查.
- 分析给药途径 (口服,阴道,透皮,子宫内) 和使用模式 (顺序,连续).
- 评估有关乳腺癌风险,深静脉血栓塞 (DVT),结直肠癌,血管健康和神经退行性疾病的数据.
主要成果:
- 持续使用孕激素提供了最有效的子宫内膜保护.
- 孕激素的添加显著增加了乳腺癌的风险;二二,微化孕激素和利沃诺格斯特勒子宫内器件可能与较低的风险有关.
- 孕激素增加了 DVT 风险的两倍,并减少了雌激素对结直肠癌和血管健康的益处,同时可能降低了血管痴呆风险.
结论:
- 孕激素对子宫内膜保护是有效的,但具有重大风险,包括增加乳腺癌和DVT.
- 孕激素的选择和给药途径会影响安全性.
- 需要进一步研究低剂量无阻抗雌激素疗法,并进行仔细的子宫内膜监测.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...